These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8623053)

  • 21. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma.
    Wong WL; Chevretton EB; McGurk M; Hussain K; Davis J; Beaney R; Baddeley H; Tierney P; Maisey M
    Clin Otolaryngol Allied Sci; 1997 Jun; 22(3):209-14. PubMed ID: 9222623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
    Buchmann I; Ganten TM; Haberkorn U
    Z Gastroenterol; 2008 Apr; 46(4):367-75. PubMed ID: 18393156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
    Gritters LS; Francis IR; Zasadny KR; Wahl RL
    J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer.
    Lonneux M; Delval D; Bausart R; Moens R; Willockx R; Van Mael P; Declerck P; Jamar F; Zreik H; Pauwels S
    Nucl Med Commun; 1998 Nov; 19(11):1047-54. PubMed ID: 9861621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma.
    Benyounes H; Smith FW; Campbell C; Evans NT; Norton MY; Mikecz P; Heys SD; Bruce D; Eremin O; Sharp PF
    Nucl Med Commun; 1995 Jul; 16(7):575-80. PubMed ID: 7478396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
    Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
    Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.
    Flanagan FL; Dehdashti F; Ogunbiyi OA; Kodner IJ; Siegel BA
    Ann Surg; 1998 Mar; 227(3):319-23. PubMed ID: 9527052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
    Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
    J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Staging recurrent metastatic colorectal carcinoma with PET.
    Delbeke D; Vitola JV; Sandler MP; Arildsen RC; Powers TA; Wright JK; Chapman WC; Pinson CW
    J Nucl Med; 1997 Aug; 38(8):1196-201. PubMed ID: 9255148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.
    Inokuma T; Tamaki N; Torizuka T; Magata Y; Fujii M; Yonekura Y; Kajiyama T; Ohshio G; Imamura M; Konishi J
    Radiology; 1995 May; 195(2):345-52. PubMed ID: 7724751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET imaging in assessing gastrointestinal tumors.
    Hustinx R
    Radiol Clin North Am; 2004 Nov; 42(6):1123-39, ix. PubMed ID: 15488562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.
    Potter KC; Husband JE; Houghton SL; Thomas K; Brown G
    Dis Colon Rectum; 2009 Feb; 52(2):253-9. PubMed ID: 19279420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
    Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
    Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Positron emission tomography (PET) in gastro-intestinal cancer].
    Wartski M
    Presse Med; 2016 Sep; 45(9):734-41. PubMed ID: 27542763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
    Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
    Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer.
    Beets G; Penninckx F; Schiepers C; Filez L; Mortelmans L; Kerremans R; Aerts R; De Roo M
    Br J Surg; 1994 Nov; 81(11):1666-70. PubMed ID: 7827902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of chest masses by FDG positron emission tomography.
    Hübner KF; Buonocore E; Singh SK; Gould HR; Cotten DW
    Clin Nucl Med; 1995 Apr; 20(4):293-8. PubMed ID: 7788982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver.
    Zhuang H; Sinha P; Pourdehnad M; Duarte PS; Yamamoto AJ; Alavi A
    Nucl Med Commun; 2000 Sep; 21(9):793-8. PubMed ID: 11065150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.